SOURCE: Hepregen Corporation

Hepregen Corporation

January 29, 2015 10:00 ET

Hepregen Launches First Dog HepatoPac® Assay Kit to Evaluate Metabolism in the Laboratory

Application-Directed Kit Complements Human, Rat and Monkey Counterparts

MEDFORD, MA--(Marketwired - January 29, 2015) - Today, Hepregen Corporation, a leader in the development of next generation HepatoPac® and HepatoMune™ cell-based in vitro assay products, announced the commercial launch of the company's first dog HepatoPac® kit designed specifically for metabolite identification and profiling applications. Each kit contains one or more standard 24-well tissue culture plates featuring uniquely configured micro-patterned dog liver cells co-cultured with specially selected stromal cells that support the highest level of performance observed in Hepregen's micro-patterned co-culture platform. The dog liver cells (hepatocytes) on these plates mirror the behavior of liver cells in live animals, enabling scientists to generate data that can be useful for evaluation of the metabolism of chemical agents, including drug candidates, improving the design of preclinical experiments.

The remarkable flexibility of Hepregen's micro-patterned HepatoPac® platform allowed Hepregen scientists to develop a dog product that provides investigators with uniquely stable canine hepatocytes. The tissue culture maintains functionality and morphology for weeks, enabling experiments not previously possible.

Dr. Vincent Zurawski, Hepregen's Chief Executive Officer stated, "This new dog product provides another HepatoPac® application-directed kit serving the drug- and chemical-metabolism market. The unprecedented performance of the kit is enabled by a proprietary species-specific set of features that may be adaptable to all live-cell, in vitro products that contain primary dog hepatocytes. The introduction of our dog kit provides customers with a complete set of products relevant to drug development: human, monkey, rat and now dog HepatoPac® kits for metabolite identification and profiling."

About Hepregen Corporation

Hepregen Corporation is a leader in innovating unique and proprietary bioengineered micro-liver platforms for use in environmental testing, preventive care, and product development in the pharmaceutical and biopharmaceutical, diagnostic, cosmetics, and chemical industries. The company's micro-liver HepatoPac® and HepatoMune™ cell-based assays are intended to drive a paradigm shift in drug development. The utility of Hepregen's human, rat, monkey, dog, and multi-species/multi-donor HepatoPac® and HepatoMune™ application-directed products has been validated in collaboration with investigators at several well-known pharmaceutical companies. Additionally, new applications for these products are being tested by Hepregen, its pharmaceutical company customers, and its academic and business partners. Hepregen was founded and capitalized by Battelle Ventures and Innovation Valley Partners with technology licensed from the Massachusetts Institute of Technology. The technology was developed by Professor Sangeeta Bhatia, who is a world renowned expert and leader in liver bioengineering for life science and therapeutic applications.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements. Such forward-looking statements reflect Hepregen Corporation's expectations about its future operating results, performance and opportunities that involve substantial risk and uncertainties. These statements include but are not limited to statements regarding the performance and results of the company's HepatoPac® application-directed kits. When used herein, the words "anticipate," "believe," "estimate," "upcoming," "plan," "target," "intend" and "expect" and similar expressions, as they relate to Hepregen Corporation or its management are intended to identify such forward-looking statements. These forward-looking statements are based on information currently available to Hepregen Corporation and are subject to a number of risks, uncertainties and other factors that could cause Hepregen Corporation's actual results, performance, prospects and opportunities to differ materially from those expressed in, or implied by, these forward-looking statements.

Image Available:

Contact Information